Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway

Anti-angiogenic therapy is one of the promising strategies for many types of solid cancers. Bevacizumab (Avastin), a recombinant humanized monoclonal antibody of vascular endothelial growth factor (VEGF) A, was approved for the first time as an anti-angiogenic drug for the treatment of metastatic co...

Descripción completa

Detalles Bibliográficos
Autores principales: Itatani, Yoshiro, Kawada, Kenji, Yamamoto, Takamasa, Sakai, Yoshiharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5979390/
https://www.ncbi.nlm.nih.gov/pubmed/29670046
http://dx.doi.org/10.3390/ijms19041232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5979390/
https://www.ncbi.nlm.nih.gov/pubmed/29670046
http://dx.doi.org/10.3390/ijms19041232

Ejemplares similares